{"id":3955,"date":"2025-03-31T18:11:54","date_gmt":"2025-03-31T18:11:54","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/esmolol-hydrochloride-txt\/"},"modified":"2025-03-31T18:11:54","modified_gmt":"2025-03-31T18:11:54","slug":"esmolol-hydrochloride-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/esmolol-hydrochloride-txt\/","title":{"rendered":"Esmolol hydrochloride.txt"},"content":{"rendered":"

Esmolol hydrochloride<\/h1>\n

CLINICAL USE <\/H3>
\nBeta-adrenoceptor blocker:Short-term treatment of supraventricular arrhythmias (including AF, atrial flutter, sinus tachycardia)Tachycardia and hypertension in the perioperative period

DOSE IN NORMAL RENAL FUNCTION <\/H3>50\u2013300 micrograms\/kg\/minute; see product literature for titration schedule

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :331.8<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :55<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : <2<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :1.9<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :9 minutes\/unchanged

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Dialysed. Dose as in normal renal function <\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Dialysed. Dose as in normal renal function
  • HDF\/high flux &nbsp :Dialysed. Dose as in normal renal function
  • CAV\/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • Anaesthetics: enhanced hypotensive effect\n
  • Analgesics: NSAIDs antagonise hypotensive effect\n
  • Anti-arrhythmics: increased risk of myocardial depression and bradycardia; with amiodarone, increased risk of bradycardia and AV block and myocardial depression\n
  • Antidepressants: enhanced hypotensive effect with MAOIs\n
  • Antimalarials: increased risk of bradycardia with mefloquine\n
  • Antipsychotics: enhanced hypotensive effect with phenothiazines\n
  • Calcium-channel blockers: increased risk of bradycardia and AV block with diltiazem; severe hypotension and heart failure occasionally with nifedipine and possibly other dihydropyridines; asystole, severe hypotension and heart failure with verapamil \u2013 avoid concomitant verapamil useAntihypertensives: enhanced hypotensive effect; increased risk of withdrawal hypertension with clonidine; increased risk of first dose hypotensive effect with post-synaptic alpha-blockers\n
  • Diuretics: enhanced hypotensive effect\n
  • Moxisylyte: possible severe postural hypotension\n
  • Sympathomimetics: severe hypertension with adrenaline and noradrenaline and possibly dobutamineTropisetron: increased risk of ventricular arrhythmias \u2013 use with caution

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>

    IV infusion <\/H4>

    Rate of Administration <\/H4>50\u2013300 mcg\/kg\/minute

    Comments<\/H4>Incompatible with sodium bicarbonate solutionsDilute to a concentration of 10 mg\/mL with sodium chloride 0.9% or glucose 5%Local irritation has occurred with infusions of 20 mg\/mL

    OTHER INFORMATION <\/H4>Has an active renally-excreted metabolite Hyperkalaemia can occur in CKD 5 Titrate dose according to blood pressure response
    \n","protected":false},"excerpt":{"rendered":"

    Esmolol hydrochloride CLINICAL USE Beta-adrenoceptor blocker:Short-term treatment of supraventricular arrhythmias<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-3955","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3955","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=3955"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3955\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=3955"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=3955"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=3955"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}